| Year |
Citation |
Score |
| 2022 |
Feuerstadt P, Louie TJ, Lashner B, Wang EEL, Diao L, Bryant JA, Sims M, Kraft CS, Cohen SH, Berenson CS, Korman LY, Ford CB, Litcofsky KD, Lombardo MJ, Wortman JR, et al. SER-109, an Oral Microbiome Therapy for Recurrent Infection. The New England Journal of Medicine. 386: 220-229. PMID 35045228 DOI: 10.1056/NEJMoa2106516 |
0.492 |
|
| 2020 |
McGovern BH, Ford CB, Henn MR, Pardi DS, Khanna S, Hohmann EL, O'Brien EJ, Desjardins CA, Bernardo P, Wortman JR, Lombardo MJ, Litcofsky KD, Winkler JA, McChalicher CWJ, Li SS, et al. SER-109, an Investigational Microbiome Drug to Reduce Recurrence after Clostridioides difficile infection: Lessons Learned from a Phase 2 Trial. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 32255488 DOI: 10.1093/Cid/Ciaa387 |
0.484 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2012 |
Litcofsky KD, Afeyan RB, Krom RJ, Khalil AS, Collins JJ. Iterative plug-and-play methodology for constructing and modifying synthetic gene networks. Nature Methods. 9: 1077-80. PMID 23042452 DOI: 10.1038/Nmeth.2205 |
0.294 |
|
| 2023 |
Straub TJ, Lombardo MJ, Bryant JA, Diao L, Lodise T, Freedberg DE, Wortman J, Litcofsky KD, Hasson BR, McGovern BH, Ford CB, Henn MR. Impact of a purified microbiome therapeutic on abundance of antimicrobial resistance genes in patients with recurrent Clostridioides difficile infection. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. PMID 37823484 DOI: 10.1093/cid/ciad636 |
0.28 |
|
| Hide low-probability matches. |